Dr. Gaasterland designs and uses computational tools to decipher and interrogate cell systems through integrated analysis of genomic and proteomic data. Her work aims to address the general question: How does regulation of transcription and translation modulate and affect cell state changes? She applies this approach to understand optic nerve degeneration in primary open-angle glaucoma (POAG). The genetics of POAG are complex; to date, no single causative genomic variant has been established as causing the disease.
Genome-wide sequencing of exons from protein-coding and non-coding genes in 333 patients with primary open angle glaucoma revealed over 100 associated SNP sites in over 70 genes. To rank and prioritize genes and generate hypotheses about molecular mechanisms disrupted by associated variant sites, mRNA and small RNA (microRNA) were sequenced from ocular tissues relevant to the disease.
Dr. Gaasterland will discuss analysis protocols and techniques for integrated data interpretation to construct putative regulatory networks underlying disease. Her approach revealed two strong candidate models explaining neurodegeneration in POAG. Data collection and analysis methods are generally applicable beyond glaucoma to other chronic, progressive diseases associated with aging.
The Bioinformatics & Pharmacogenomics: Managing and Analyzing Big Data Conference brings together a mix of academic and industry experts from leading affiliations (such as GSK, Takeda, Johns Hopkins, UCSD, Stanford, UCLA) to cover current and relevant aspects of sequencing platforms, data integration, personal genomics and pharmacogenomics.
This conference is also part of the Nucleic Acid Summit, which consists of this and three other conferences:
4th Next-Generation SequencingNon-Coding RNAs and RNAi Research & TherapeuticsNucleic Acid Research & Discovery
For more information, please visit http://www.gtcbio.com/bioinformatics
GTCBio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.
Global Technology Community LLC (GTCBio), is a privately-held company founded in 2002.
| < Prev | Next > |
|---|
